The Food and Drug Administration has approved Brilinta to reduce the risk of a first myocardial infarction or stroke in high-risk patients with coronary artery disease.
The risk for recurrent stroke was found to be better predicted by atrial septal aneurysm status than by interatrial shunt size in patients with patent foramen ovale-related ischemic stroke.
A panel prepared a comprehensive set of practice implications for clinicians caring for adults with acute ischemic stroke with confirmed or suspected of having COVID-19.
In light of the changes inflicted by the COVID-19 pandemic, the researchers wished to explore the effects of the pandemic on stroke management during the first month of Italy’s lockdown.
Low mean levels and high variability of HDL-C were found to be associated with increased risks for stroke, myocardial infarction and all-cause mortality.
Oral anticoagulation with or without antiplatelet medication was found to increase the risk for bleeding, with minimal protective effect against ischemic stroke in patients with heart failure with reduced ejection fraction and sinus rhythm.
Patients with chronic lower extremity artery disease treated with a more vs less intensive antithrombotic therapeutic regimen were found to be at lower risk for limb amputation, stroke, and revascularization.
